FDA to withdraw approval of swine drug due to food safety concerns
FDA’s Center for Veterinary Medicine (CVM) is taking the first step toward rescinding its approval of the use of carbadox to treat swine because the regulatory agency says the drug may leave trace amounts of a carcinogenic residue and could pose a potential risk to human health from pork consumption, especially pork liver.
“The manufacturer of carbadox has failed to provide sufficient scientific data to demonstrate the safety of this drug given evidence that carbadox may result in carcinogenic residues,” says Michael Taylor, FDA deputy commissioner for foods and veterinary medicine. “As a result, FDA’s Center for Veterinary Medicine is taking legal action to remove this product from the marketplace.”